The objectives encompass an assessment of binding affinities through molecular docking, analyzing pharmacokinetic and drug-likeness characteristics, in-silico toxicity analysis, synthesis, and characterization of selected compounds. Molecular docking analysis was conducted to evaluate the binding affinities of these derivatives with the EGFR protein. Lipinski's rule of five were applied to assess pharmacokinetic properties. An in-silico toxicity assessment focused on parameters such as LD50, toxicity classification, and the probability of hepatotoxicity, carcinogenicity, immunotoxicity, mutagenicity, and cytotoxicity. The selected compounds were synthesized and characterized using Fourier-transform infrared spectroscopy (FTIR), proton nuclear magnetic resonance spectroscopy (1H NMR), and mass spectrometry (MS). The molecular docking studies reveal binding affinities between the derivatives and EGFR. All compounds adhered to Lipinski's rule of five and Veber's rule, suggesting favorable drug-likeness and oral bioavailability. Pharmacokinetic profiles indicated high gastrointestinal absorption. In-silico toxicity analysis revealed a consistent safety profile across all compounds. The synthesized compounds were characterized successfully using FTIR, 1H NMR, and MS techniques. 2-phenyl-1H-benzo[d]imidazole derivatives exhibit substantial potential as EGFR inhibitors, with promising pharmacokinetic characteristics and an overall safe toxicity profile. The compounds Sb19 and Sb25 exhibited the most promising cytotoxic and growth inhibitory effects against the MCF-7 cell line, suggesting their potential as effective anticancer agents. These findings warrant further investigation into their mechanisms of action and therapeutic applications.